Fu's needle therapy for dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a needle technique called Fu's subcutaneous needling for people with dry age-related macular degeneration (AMD). It aims to see if this treatment can help improve vision or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have dry age-related macular degeneration (AMD) as diagnosed by a doctor.
- You are willing to sign a consent form and come for follow-up visits.
- You have not had eye surgery in the past 6 months.
- You are not pregnant or breastfeeding.
- You do not have other serious eye diseases or conditions that affect vision (like wet AMD, glaucoma, or mature cataracts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called faricimab for people with wet age-related macular degeneration (AMD) that hasn't improved enough with standard anti-VEGF shots. The goal is to see if faricimab can reduce retinal fluid and improve vision in patients who still have fluid despite many previous treatments.
This trial tests a traditional Chinese medicine pill, Sanhuang Jingshiming, for people with a specific type of wet age-related macular degeneration (nAMD) that is active. It aims to see if the pill can help improve vision and is safe compared to standard care.
This study tests whether a new eye drop medication (SCAI-005) can help people with wet age-related macular degeneration (a serious eye condition affecting central vision in older adults) who have already responded well to regular eye injections. The goal is to see if eye drops might work as an alternative treatment.
This study observes how a drug called faricimab works in treating wet AMD (a condition affecting central vision in older adults). You would receive four initial injections into your eye, then additional injections as needed based on your response.
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
Hear when a new Age - Related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.